FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia With a NPM1 Mutation

On November 13, the FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.

For more information, read the FDA announcement and the Kura Oncology press release.

Posted on 11/14/2025